Schistosoma Haematobium Infections and Praziquantel

University of Khartoum

Status and phase: Completed; Phase 3

Conditions: Schistosomiasis

Treatments: Drug: praziquantel

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01558336

Schistosmiasis

Details and patient eligibility

About

The purpose of this study is to evaluate the impact of praziquantel for the treatment of Schistosoma haematobium infection among schoolchildren in Al Salamania in Central Sudan.

Full description

A longitudinal study will be conducted to evaluate the impact of praziquantel for the treatment of Schistosoma haematobium infection among schoolchildren in Al Salamania in Central Sudan. A cohort of schoolchildren (6-15 years of age) was investigated before and 1 year after treatment with a single dose of praziquantel 40mg/kg.

Enrollment: 520 patients

Sex: All

Ages: 6 to 15 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• School children

Exclusion criteria

• Taking praziquantel

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

520 participants in 1 patient group

Praziguantel

Experimental group

Description:

tablet single dose

Treatment:

Drug: praziquantel